GP 53633
Latest Information Update: 16 Feb 1995
Price :
$50 *
At a glance
- Originator Novartis
- Class Antirheumatics; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatic disorders
Most Recent Events
- 16 Feb 1995 Discontinued-Preclinical for Rheumatic disorders (Unknown route)